Research Articles | Page 8 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria Jan 2021 Leukemia Paroxysmal Nocturnal Hemoglobinuria (PNH)
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS Jun 2020 Leukemia Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL) Jun 2020 Leukemia Myelodysplastic Syndromes (MDS)
Rethinking clinical trial endpoints in myelodysplastic syndromes. Jan 2019 Leukemia Myelodysplastic Syndromes (MDS)
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study Oct 2023 Leukemia Aplastic Anemia
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Jan 2019 Leuk Lymphoma. Myelodysplastic Syndromes (MDS)
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT Oct 2023 Lancet Hematology Myelodysplastic Syndromes (MDS)
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial Aug 2020 Lancet Hematology Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)